Comparative study on association between serum TSH concentration and Thyroid cancer

Prasad C.; Supreet Kumar; Tej Tej Y.

doi:10.18203/2349-2902.isj20173422

Authors

Prasad C. Department of Surgery, BGS Global Institute of Medical Sciences, Bangalore, Karnataka, India
Supreet Kumar Department of Surgery, SCBMCH, Cuttack, Orissa, India
Tej Tej Y. Associate Professor, Department of Surgery, SCBMCH, Cuttack, Orissa, India

DOI:

https://doi.org/10.18203/2349-2902.isj20173422

Keywords:

Thyroid malignancy, Thyroid nodule, Thyroid stimulating hormone

Abstract

Background: In India, thyroid cancer accounts for less than 1% of all malignancies (2% of women and 0.5% of men). Thyroid cancer is responsible for 6 deaths per 1 million persons annually. Serum TSH is a well-established growth factor for thyroid nodules, however its role in thyroid malignancy is inconclusive hence this study was conducted with the objective to determine the association between serum Thyroid stimulating hormone (TSH) concentrations with thyroid carcinoma.

Methods: Case control study was conducted in a tertiary care centre. 120 Benign and malignant thyroid subjects respectively were included in the study. Newly diagnosed and record based data collection was done. Measurements of serum TSH concentrations were performed by automated immune chemiluminescent assay. Data was analyzed using SPSS 22 version software, Chi-square test was used as test of significance for qualitative data, p value of <0.05 was considered as statistically significant.

Results: Majority of them were females in the age group 26 to 40 years in both the groups and were diagnosed to have solitary thyroid nodule. In malignant thyroid nodules 51.7% were diagnosed to have follicular carcinoma, 46.7% had papillary carcinoma and 1.7% were diagnosed to have Hurthle cell carcinoma. Significant association was observed between TSH levels and diagnosis of thyroid lesions. TSH was raised (>4mIU/L) in 46.6% of malignant nodules and in 15% of benign nodules. Raised TSH had an odds ratio of 4.958 for Thyroid malignancy compared to benign nodules

Conclusions: Higher TSH levels were associated with Thyroid malignancy and the risk of malignancy rises in parallel with serum TSH within normal range, and high levels of serum TSH concentrations was associated with advanced stage of thyroid cancer.

Metrics

Metrics Loading ...

Author Biographies

Prasad C., Department of Surgery, BGS Global Institute of Medical Sciences, Bangalore, Karnataka, India

Assistant Professor
BGS Global Institute of Medical Sciences, Bangalore

Supreet Kumar, Department of Surgery, SCBMCH, Cuttack, Orissa, India

Junior Resident, Department of Surgery, SCBMCH, Cuttack, Orissa, India

Tej Tej Y., Associate Professor, Department of Surgery, SCBMCH, Cuttack, Orissa, India

Department of Surgery, SCBMCH, Cuttack, Orissa, India

References

Nagataki S, Nystrom E. Epidemiology and primary prevention of thyroid cancer. Thyroid. 2002;12(10):889-96.

Fiore E, Rago T, Provenzale MA, Scutari M, Ugolini C, Basolo F, et al. Lower levels of TSH are associated to a lower risk of papillary thyroid cancer in patients with thyroid nodular disease: thyroid autonomy may play a protective role. Endocr Relat Cancer. 2009;16(4):1251-60.

Brewer C, Yeager N, Di Cristofano A. Thyroid-stimulating hormone initiated proliferative signals converge in vivo on the mTOR kinase without activating AKT. Cancer Res. 2007;67:8002-6.

Hedinger C, Williams ED, Sobin LH. Histological typing tumours. Second edition. No.11 in: International Histological Classification of Tumours, World Health Organization. Springer -Verlag, Berlin. 1988.

Gharib H. Changing trends in thyroid practice: understanding nodular thyroid disease. Endocr Pract. 2004;10:31-39.

Papini E, Petrucci L, Guglielmi R, Panunzi CR. Rinaldi, V Bacci, et al. Long-term changes in nodular goitre: a 5-year prospective randomized trial of levothyroxine suppressive therapy for benign cold thyroid nodules. J Clin Endocrinol Metab. 1998;83:780-3.

Hegedüs L, Bonnema SJ, Bennedbaek FN . Management of simple nodular goitre: current status and future perspectives. Endocr Rev. 2003;24(1):102-132.

Walsh RM, Watkinson JC, Franklyn. The management of solitary thyroid nodule. Clinotolayngol. 1999;24:388-97.

Vermiglio F, Lo Presti VP, Violi MA, Moleti M, Castagna MG, Finocchiaro MD, et al. Changes in both size and cytological features of thyroid nodule after levothyroxine treatment. Clin Endocrinol (Oxf). 2003;59(3):347-353.

Pujol P, Daures JP, Nsakala N, Baldet L, Bringer J, Jaffiol C. Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J Clin Endocrinol Metabol. 1996;81(11):4318-23.

Ichikawa Y, Saito E, Abe Y, Homma M, Muraki T. Presence of TSH receptor in thyroid neoplasms”. J Clin Endocrinol Metabol. 1976;42:395-98.

Kimura T, Van Keymeulen A, Golstein J, Fusco A, Dumont JE, Roger PP. Regulation of thyroid cell proliferation by TSH and other factors: a critical evaluation of in vitro models. Endocrine Reviews. 22(5):631-56.

Jonklaas J, Nsouli-Maktabi H, Soldin SJ. Endogenous thyrotropin and triiodothyronine concentrations in individuals with thyroid cancer. Thyroid. 2008;18(9):943-52.

Boelaert K, Horacek J, Holder RL, Watkinson JC, Sheppard MC, Franklyn JA. Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodule investigated by fine-needle aspiration. J Clin Endocrinol Metab. 2006;91(11):4295-301.

Polyzos SA, Kita M, Efstathiadou Z, Poulakos P, Slavakis A, Sofianou D, et al. Serum thyrotropin concentration as biochemical predictor of thyroid malignancy in patients presenting with thyroid nodules. J Cancer Res Clin Oncol. 2008;134(9):953-60.

Rist MR, Repplinger DJ, Leverson GE, Elson DF, Sippel RS, Jaume JC, et al. Higher serum thyroid stimulating hormone level in thyroid nodule patients is associate with greater risks of differentiated thyroid cancer and advanced tumor stage. J Clin Endocrinol Metab. 2008;93(3):809-14.